Litigation

Recent Posts

3rd Levaquin MDL Bellwether Trial Ends With 3rd Verdict For Johnson & Johnson
Posted on 27 Jan 2012 by Tom Moylan

MINNEAPOLIS - (Mealey's) The third Levaquin multidistrict litigation tendon rupture trial ended Jan. 26 with a defense verdict, defendant Johnson & Johnson's third compared to one plaintiff victory ( Clifford Straka v. Johnson & Johnson... Read More

Tags: Minnesota Senior Citizen and Disabled Person's Consumer Fraud and Deceptive Trade Practices Act , drugs , Clifford Straka , Minnesota Consumer Fraud Act , Johnson , Levaquin , tendon rupture , Litigation , multidistrict litigation , Clifford Straka v. Johnson &amp , verdict , Janssen Pharmaceuticals , Johnson &amp

First New Jersey Levaquin Tendon Injury Trial Ends With Defense Verdict
Posted on 14 Oct 2011 by Tom Moylan

ATLANTIC CITY, N.J. - (Mealey's) The first trial in New Jersey's Levaquin mass tort litigation ended Oct. 14 with a defense verdict for Johnson & Johnson and subsidiary Ortho-McNeil-Janssen Pharmaceuticals Inc. ( Paul Gaffney v. Johnson &... Read More

Tags: black box warning , Paul Gaffney v. Johnson &amp , Beare , tendonitis , Johnson , Levaquin , fluoroquinolone , New Jersey , tendon rupture , Atlantic County Superior Court , drugs and devices , Litigation , antibiotic , Gaffney , Robert and Judith Beare v. Johnson &amp , Ortho-McNeil-Janssen Pharmaceuticals , mass tort , Johnson &amp

Texas Risperdal Trial Ends When Janssen Settles For $158 Million, Company Says
Posted on 19 Jan 2012 by Tom Moylan

AUSTIN, Texas -- Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal... Read More

Tags: Travis County District Court , Risperdal , off-label promotion , State of Texas v. Janssen LP , Johnson , Medicaid , Litigation , Settlement , Janssen LLP , Texas , Johnson &amp , antipsychotic drug

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

Tags: Gary D. Skala , drugs , Risperdal , et al. , Johnson , personal injury , AstraZeneca , New Jersey , Gary D. Skala v. Johnson &amp , Litigation , amp , mass tort , Eli Lilly and Co. , Zyprexa , verdict , diabetes , Seroquel , Janssen Pharmaceuticals , Johnson &amp , antipsychotic drug

New Jersey Jury Awards $3.35 Million, Weighs Punitives In State's 1st Pelvic Mesh Trial
Posted on 26 Feb 2013 by Tom Moylan

ATLANTIC CITY, N.J. - (Mealey's) A New Jersey court on Feb. 26 is hearing evidence for a punitive damages verdict in the state's first pelvic mesh bellwether trial, a day after returning a $3.35 million compensatory verdict for a woman who claims... Read More

Tags: punitive damages , Linda Gross v. Ethicon , Linda Gross , pelvic mesh , Johnson , Gynecare Prolift pelvic mesh sling , Atlantic County Superior Court , Litigation , In Re Pelvic Mesh / Gynecare Litigation , verdict , Johnson &amp , drugs and medical devices , Ethicon Endo-Surgery Inc.

California State Jury Awards $48.1 Million In Motrin Injury Case
Posted on 4 Oct 2011 by Tom Moylan

LOS ANGELES - (Mealey's) A California state court jury on Oct. 3 awarded $48.1 million to a 22-year-old man who says Johnson & Johnson and subsidiary McNeil Consumer Healthcare failed to warn him that the nonprescription pain and fever remedy... Read More

Tags: Christopher Trejo , TEN , Johnson , toxic epidermal necrolysis , McNeil Consumer Healthcare , Motrin , drugs and devices , Litigation , Christopher Trejo v. Johnson &amp , ibuprofen , jury award , Johnson &amp

Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases
Posted on 11 Jun 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) Johnson & Johnson (J&J) expects to incur a special charge against earnings of about $600 million in the second quarter for the potential settlement of civil litigation related to Risperdal, Invega, Natrecor... Read More

Tags: SEC civil cases , Risperdal , Johnson , Natrecor , Invega , amp , Johnson &amp

Arkansas Judge Orders J&J Unit To Pay $1.1 Billion Penalty For Risperdal Marketing
Posted on 12 Apr 2012 by Tom Moylan

LITTLE ROCK, Ark. - (Mealey's) An Arkansas state court judge on April 11 assessed a $1.1 billion penalty against the Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson for thousands of violations of state trade practice... Read More

Tags: Ortho-McNeil-Janssen Pharmaceuticals Inc. , Risperdal , Johnson , State of Arkansas v. Ortho-McNeil-Janssen Pharmaceuticals Inc. , Mealey Publications , Medicaid frauds , Litigation , Johnson &amp , antipsychotic drug

Massachusetts Jury Awards $63 Million To Girl, Parents For Children's Motrin Injuries
Posted on 14 Feb 2013 by Tom Moylan

BROCKTON, Mass. - (Mealey's) A Massachusetts state court jury on Feb. 13 awarded $63 million to a family whose young daughter was severely injured by a reaction to Children's Motrin ( Lisa Reckis, et al. v. Johnson & Johnson, et al. , No.... Read More

Tags: Jordan Hospital , Samantha T. Reckis , Massachusetts , Children's Motrin , Johnson , toxic epidermal necrolysis , Lisa Reckis v. Johnson &amp , TENs , McNeil-PPC Inc. , drugs and devices , Litigation , amp , failure to warn , Plymouth County Superior Court , loss of consortium , jury award , Johnson &amp

Scios To Plead Guilty, Pay $85 Million For Off-Label Marketing Of Natrecor
Posted on 15 Sep 2011 by Tom Moylan

SAN FRANCISCO -- The Scios Inc. subsidiary of Johnson & Johnson has agreed to plead guilty to a misdemeanor charge related to the off-label marketing of its Natrecor heart drug, to pay an $85 million fine and to serve three years' organizational... Read More

Tags: False Claims Act , heart drug , off-label marketing , United States of America v. Scios , Johnson , Natrecor , Food Drug and Cosmetic Act , Scios , Litigation , Johnson &amp